Aligos Therapeutics Presents NASH Asset Development Update at The Liver Meeting® 2019

Aligos poster presentation, titled Preclinical development of ALG-055009 as a Potent and Selective Thyroid Hormone Receptor Beta Agonist for the Treatment of NASH, highlighted key preclinical data for the companys lead NASH candidate ALG-055009, a thyroid hormone receptor- (THR-) agonist.